Research programme: phosphatidylinositol 3-kinase inhibitors - Karus Therapeutics

Drug Profile

Research programme: phosphatidylinositol 3-kinase inhibitors - Karus Therapeutics

Alternative Names: KAR-4000; KAR1139; KAR1141; Lipid kinase signaling inhibitors - Karus; PI3K-p110 beta; PI3K-p110 delta

Latest Information Update: 20 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karus Therapeutics
  • Developer Karus Therapeutics; University of London
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 17 Dec 2012 Karus Therapeutics enters into a collaboration with the Babraham Institue to further characterise its PI3K inhibitors for inflammatory diseases
  • 07 Sep 2012 Preclinical development is ongoing in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top